Immune response to enzyme replacement therapies in lysosomal storage diseases and the role of immune tolerance induction

Priya S. Kishnani; Patricia I. Dickson; Laurie Muldowney; Jessica J. Lee; Amy Rosenberg; Rekha Abichandani; Jeffrey A. Bluestone; Barbara K. Burton; Maureen Dewey; Alexandra Freitas; Derek Gavin; Donna Griebel; Melissa Hogan; Stephen Holland; Pranoot Tanpaiboon; Laurence A. Turka; Jeanine J. Utz; Yow Ming Wang; Chester B Whitley; Zoheb B. Kazi; Anne R. Pariser

doi:10.1016/j.ymgme.2015.11.001

Immune response to enzyme replacement therapies in lysosomal storage diseases and the role of immune tolerance induction

Priya S. Kishnani, Patricia I. Dickson, Laurie Muldowney, Jessica J. Lee, Amy Rosenberg, Rekha Abichandani, Jeffrey A. Bluestone, Barbara K. Burton, Maureen Dewey, Alexandra Freitas, Derek Gavin, Donna Griebel, Melissa Hogan, Stephen Holland, Pranoot Tanpaiboon, Laurence A. Turka, Jeanine J. Utz, Yow Ming Wang, Chester B Whitley, Zoheb B. KaziAnne R. Pariser

Pediatrics - Genetics and Metabolism

Research output: Contribution to journal › Review article › peer-review

59 Scopus citations

Abstract

The US Food and Drug Administration (FDA) and National Organization for Rare Disease (NORD) convened a public workshop titled "Immune Responses to Enzyme Replacement Therapies: Role of Immune Tolerance Induction" to discuss the impact of anti-drug antibodies (ADAs) on efficacy and safety of enzyme replacement therapies (ERTs) intended to treat patients with lysosomal storage diseases (LSDs). Participants in the workshop included FDA staff, clinicians, scientists, patients, industry, and advocacy group representatives. The risks and benefits of implementing prophylactic immune tolerance induction (ITI) to reduce the potential clinical impact of antibody development were considered. Complications due to immune responses to ERT are being recognized with increasing experience and lengths of exposure to ERTs to treat several LSDs. Strategies to mitigate immune responses and to optimize therapies are needed. Discussions during the workshop resulted in the identification of knowledge gaps and future areas of research, as well as the following proposals from the participants: (1) systematic collection of longitudinal data on immunogenicity to better understand the impact of ADAs on long-term clinical outcomes; (2) development of disease-specific biomarkers and outcome measures to assess the effect of ADAs and ITI on efficacy and safety; (3) development of consistent approaches to ADA assays to allow comparisons of immunogenicity data across different products and disease groups, and to expedite reporting of results; (4) establishment of a system to widely share data on antibody titers following treatment with ERTs; (5) identification of components of the protein that are immunogenic so that triggers and components of the immune responses can be targeted in ITI; and (6) consideration of early ITI in patients who are at risk of developing clinically relevant ADA that have been demonstrated to worsen treatment outcomes.

Original language	English (US)
Pages (from-to)	66-83
Number of pages	18
Journal	Molecular Genetics and Metabolism
Volume	117
Issue number	2
DOIs	https://doi.org/10.1016/j.ymgme.2015.11.001
State	Published - Feb 1 2016

Bibliographical note

Publisher Copyright:
© 2015 Published by Elsevier Inc.

Keywords

Enzyme replacement therapy
Immune tolerance
Inborn errors of metabolism
Lysosomal storage diseases
Neutralizing antibodies
Orphan drugs
Rare diseases

Access

10.1016/j.ymgme.2015.11.001

OpenUrl availability

Full text

Cite this

Kishnani, P. S., Dickson, P. I., Muldowney, L., Lee, J. J., Rosenberg, A., Abichandani, R., Bluestone, J. A., Burton, B. K., Dewey, M., Freitas, A., Gavin, D., Griebel, D., Hogan, M., Holland, S., Tanpaiboon, P., Turka, L. A., Utz, J. J., Wang, Y. M., Whitley, C. B., ... Pariser, A. R. (2016). Immune response to enzyme replacement therapies in lysosomal storage diseases and the role of immune tolerance induction. Molecular Genetics and Metabolism, 117(2), 66-83. https://doi.org/10.1016/j.ymgme.2015.11.001

Kishnani, PS, Dickson, PI, Muldowney, L, Lee, JJ, Rosenberg, A, Abichandani, R, Bluestone, JA, Burton, BK, Dewey, M, Freitas, A, Gavin, D, Griebel, D, Hogan, M, Holland, S, Tanpaiboon, P, Turka, LA, Utz, JJ, Wang, YM, Whitley, CB, Kazi, ZB & Pariser, AR 2016, 'Immune response to enzyme replacement therapies in lysosomal storage diseases and the role of immune tolerance induction', Molecular Genetics and Metabolism, vol. 117, no. 2, pp. 66-83. https://doi.org/10.1016/j.ymgme.2015.11.001

@article{66da316462144a618e30e12a60b27b10,

title = "Immune response to enzyme replacement therapies in lysosomal storage diseases and the role of immune tolerance induction",

abstract = "The US Food and Drug Administration (FDA) and National Organization for Rare Disease (NORD) convened a public workshop titled {"}Immune Responses to Enzyme Replacement Therapies: Role of Immune Tolerance Induction{"} to discuss the impact of anti-drug antibodies (ADAs) on efficacy and safety of enzyme replacement therapies (ERTs) intended to treat patients with lysosomal storage diseases (LSDs). Participants in the workshop included FDA staff, clinicians, scientists, patients, industry, and advocacy group representatives. The risks and benefits of implementing prophylactic immune tolerance induction (ITI) to reduce the potential clinical impact of antibody development were considered. Complications due to immune responses to ERT are being recognized with increasing experience and lengths of exposure to ERTs to treat several LSDs. Strategies to mitigate immune responses and to optimize therapies are needed. Discussions during the workshop resulted in the identification of knowledge gaps and future areas of research, as well as the following proposals from the participants: (1) systematic collection of longitudinal data on immunogenicity to better understand the impact of ADAs on long-term clinical outcomes; (2) development of disease-specific biomarkers and outcome measures to assess the effect of ADAs and ITI on efficacy and safety; (3) development of consistent approaches to ADA assays to allow comparisons of immunogenicity data across different products and disease groups, and to expedite reporting of results; (4) establishment of a system to widely share data on antibody titers following treatment with ERTs; (5) identification of components of the protein that are immunogenic so that triggers and components of the immune responses can be targeted in ITI; and (6) consideration of early ITI in patients who are at risk of developing clinically relevant ADA that have been demonstrated to worsen treatment outcomes.",

keywords = "Enzyme replacement therapy, Immune tolerance, Inborn errors of metabolism, Lysosomal storage diseases, Neutralizing antibodies, Orphan drugs, Rare diseases",

author = "Kishnani, {Priya S.} and Dickson, {Patricia I.} and Laurie Muldowney and Lee, {Jessica J.} and Amy Rosenberg and Rekha Abichandani and Bluestone, {Jeffrey A.} and Burton, {Barbara K.} and Maureen Dewey and Alexandra Freitas and Derek Gavin and Donna Griebel and Melissa Hogan and Stephen Holland and Pranoot Tanpaiboon and Turka, {Laurence A.} and Utz, {Jeanine J.} and Wang, {Yow Ming} and Whitley, {Chester B} and Kazi, {Zoheb B.} and Pariser, {Anne R.}",

note = "Publisher Copyright: {\textcopyright} 2015 Published by Elsevier Inc.",

year = "2016",

month = feb,

day = "1",

doi = "10.1016/j.ymgme.2015.11.001",

language = "English (US)",

volume = "117",

pages = "66--83",

journal = "Molecular Genetics and Metabolism",

issn = "1096-7192",

publisher = "Academic Press Inc.",

number = "2",

}

TY - JOUR

T1 - Immune response to enzyme replacement therapies in lysosomal storage diseases and the role of immune tolerance induction

AU - Kishnani, Priya S.

AU - Dickson, Patricia I.

AU - Muldowney, Laurie

AU - Lee, Jessica J.

AU - Rosenberg, Amy

AU - Abichandani, Rekha

AU - Bluestone, Jeffrey A.

AU - Burton, Barbara K.

AU - Dewey, Maureen

AU - Freitas, Alexandra

AU - Gavin, Derek

AU - Griebel, Donna

AU - Hogan, Melissa

AU - Holland, Stephen

AU - Tanpaiboon, Pranoot

AU - Turka, Laurence A.

AU - Utz, Jeanine J.

AU - Wang, Yow Ming

AU - Whitley, Chester B

AU - Kazi, Zoheb B.

AU - Pariser, Anne R.

PY - 2016/2/1

Y1 - 2016/2/1

N2 - The US Food and Drug Administration (FDA) and National Organization for Rare Disease (NORD) convened a public workshop titled "Immune Responses to Enzyme Replacement Therapies: Role of Immune Tolerance Induction" to discuss the impact of anti-drug antibodies (ADAs) on efficacy and safety of enzyme replacement therapies (ERTs) intended to treat patients with lysosomal storage diseases (LSDs). Participants in the workshop included FDA staff, clinicians, scientists, patients, industry, and advocacy group representatives. The risks and benefits of implementing prophylactic immune tolerance induction (ITI) to reduce the potential clinical impact of antibody development were considered. Complications due to immune responses to ERT are being recognized with increasing experience and lengths of exposure to ERTs to treat several LSDs. Strategies to mitigate immune responses and to optimize therapies are needed. Discussions during the workshop resulted in the identification of knowledge gaps and future areas of research, as well as the following proposals from the participants: (1) systematic collection of longitudinal data on immunogenicity to better understand the impact of ADAs on long-term clinical outcomes; (2) development of disease-specific biomarkers and outcome measures to assess the effect of ADAs and ITI on efficacy and safety; (3) development of consistent approaches to ADA assays to allow comparisons of immunogenicity data across different products and disease groups, and to expedite reporting of results; (4) establishment of a system to widely share data on antibody titers following treatment with ERTs; (5) identification of components of the protein that are immunogenic so that triggers and components of the immune responses can be targeted in ITI; and (6) consideration of early ITI in patients who are at risk of developing clinically relevant ADA that have been demonstrated to worsen treatment outcomes.

AB - The US Food and Drug Administration (FDA) and National Organization for Rare Disease (NORD) convened a public workshop titled "Immune Responses to Enzyme Replacement Therapies: Role of Immune Tolerance Induction" to discuss the impact of anti-drug antibodies (ADAs) on efficacy and safety of enzyme replacement therapies (ERTs) intended to treat patients with lysosomal storage diseases (LSDs). Participants in the workshop included FDA staff, clinicians, scientists, patients, industry, and advocacy group representatives. The risks and benefits of implementing prophylactic immune tolerance induction (ITI) to reduce the potential clinical impact of antibody development were considered. Complications due to immune responses to ERT are being recognized with increasing experience and lengths of exposure to ERTs to treat several LSDs. Strategies to mitigate immune responses and to optimize therapies are needed. Discussions during the workshop resulted in the identification of knowledge gaps and future areas of research, as well as the following proposals from the participants: (1) systematic collection of longitudinal data on immunogenicity to better understand the impact of ADAs on long-term clinical outcomes; (2) development of disease-specific biomarkers and outcome measures to assess the effect of ADAs and ITI on efficacy and safety; (3) development of consistent approaches to ADA assays to allow comparisons of immunogenicity data across different products and disease groups, and to expedite reporting of results; (4) establishment of a system to widely share data on antibody titers following treatment with ERTs; (5) identification of components of the protein that are immunogenic so that triggers and components of the immune responses can be targeted in ITI; and (6) consideration of early ITI in patients who are at risk of developing clinically relevant ADA that have been demonstrated to worsen treatment outcomes.

KW - Enzyme replacement therapy

KW - Immune tolerance

KW - Inborn errors of metabolism

KW - Lysosomal storage diseases

KW - Neutralizing antibodies

KW - Orphan drugs

KW - Rare diseases

UR - http://www.scopus.com/inward/record.url?scp=84957894648&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84957894648&partnerID=8YFLogxK

U2 - 10.1016/j.ymgme.2015.11.001

DO - 10.1016/j.ymgme.2015.11.001

M3 - Review article

C2 - 26597321

AN - SCOPUS:84957894648

SN - 1096-7192

VL - 117

SP - 66

EP - 83

JO - Molecular Genetics and Metabolism

JF - Molecular Genetics and Metabolism

IS - 2

ER -

Immune response to enzyme replacement therapies in lysosomal storage diseases and the role of immune tolerance induction

Abstract

Bibliographical note

Keywords

Access

OpenUrl availability

Other files and links

Fingerprint

Cite this